|
1 Indications And Usage Fasenra Is Indicated For The Add-On Maintenance Treatment Of Patients With Severe Asthma Aged 12 Years And Older, And With An Eosinophilic Phenotype [See Clinical Studies (14) ] . Limitations Of Use: • Fasenra Is Not Indicated For Treatment Of Other Eosinophilic Conditions. • Fasenra Is Not Indicated For The Relief Of Acute Bronchospasm Or Status Asthmaticus. Fasenra Is An Interleukin-5 Receptor Alpha-Directed Cytolytic Monoclonal Antibody (Igg1, Kappa) Indicated For The Add-On Maintenance Treatment Of Patients With Severe Asthma Aged 12 Years And Older, And With An Eosinophilic Phenotype. (1) Limitations Of Use: • Not For Treatment Of Other Eosinophilic Conditions. (1) • Not For Relief Of Acute Bronchospasm Or Status Asthmaticus. (1)
|